LIBTAYO study results

LIBTAYO was studied in a clinical trial that compared patients with advanced NSCLC who received LIBTAYO at 350 mg every 3 weeks with those who received chemotherapy containing platinum. The study was designed to include patients if their tumor tested positive for the biomarker PD-L1 at a level greater than or equal to 50% and if they did not have abnormal EGFR, ALK, or ROS1 genes. A total of 710 patients were included in the study.

In a study, LIBTAYO was proven to help patients live longer versus chemotherapy

Median overall survival (OS)*

Median overall survival (OS). Libtayo and chemotherapy.

*Median overall survival (OS) is the time in a trial—expressed in months or years—when half of the patients are still living.

  • Results showed that 248 out of 356 patients (70%) taking LIBTAYO were alive, compared with 213 out of 354 patients (60%) taking chemotherapy

LIBTAYO reduced the risk of cancer spreading, growing, or getting worse by 41% compared with chemotherapy.

  • Half of the patients on LIBTAYO were alive without their cancer spreading, growing, or getting worse at 6.2 months, compared with 5.6 months for patients on chemotherapy
  • Cancer had not progressed in 155 out of 356 patients (43%) taking LIBTAYO compared with 92 out of 354 patients (26%) taking chemotherapy

LIBTAYO may not work for everyone.

Review the most common side effects
of LIBTAYO in the study.

Side effects in the LIBTAYO study